Headquartered in New Haven, CT,Achillion applies expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving the lives of patients. More...
Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.
Deutsche Bank 2014 BioFEST
Piper Jaffray 26th Annual Healthcare Conference
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology